Last mentioned: Feb 26, 2026
Commercial Ramp-Up
Targeted date for full-scale commercial isotope production and revenue growth.
QLE Spin-Off Planning
Strategic restructuring to separate enrichment tech from product verticals.
Emerging Growth Conference
CEO Paul Mann provides update on isotope production and 2026 strategy.
Silicon-28 Shipments
First shipments of high-purity Silicon-28 sent to semiconductor customers.
ASP Isotopes CEO Paul Mann outlined a strategic transition to a 2026 commercial ramp-up, highlighting progress in Silicon-28 shipments and a planned spin-off of its Quantum Laser Enrichment division. The company aims to address critical global shortages in medical isotopes and advanced materials for the semiconductor and nuclear sectors.
This page surfaces every story mentioning ASP Isotopes across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where ASP Isotopes was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |